Literature DB >> 414951

Application of an improved single-radial-immunodiffusion technique for the assay of haemagglutinin antigen content of whole virus and subunit influenza vaccines.

J M Wood, G C Schild, R W Newman, V Seagroatt.   

Abstract

An improved single-radial-diffusion technique for the assay of influenza haemagglutinin antigen is described. The modified method enables the results of assays of antigen to be obtained more rapidly and with greater precision than previously. The use of immunoplates containing varied, preselected concentrations of antihaemagglutinin antibody allows accurate assays to be performed over a wide range of antigen concentration. In tests on "whole virus" antigen preparations it was found that the ratio between haemagglutination titre (iu/ml) and haemagglutinin antigen activity (microgram/ml) determined by single-radial-diffusion was relatively constant for antigens containing a given strain but showed variation between strains (range 16.5 to 26.8 iu/microgram HA activity). For the subunit vaccines examined this ratio showed a large degree of variation (range 1.4 to 16.6 iu/microgram HA activity) and in general was considerably lower than for whole virus antigens. It was concluded that single-radial-diffusion may be of value for assays of the haemagglutinin concentration of both "whole virus" vaccines and subunit vaccines. The data presented suggest that, in the event of antigenic drift, it may be possible to use the existing reference anti-haemagglutinin serum to assay a variant strain of influenza virus.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 414951

Source DB:  PubMed          Journal:  Dev Biol Stand        ISSN: 0301-5149


  16 in total

Review 1.  Age effects on B cells and humoral immunity in humans.

Authors:  Daniela Frasca; Alain Diaz; Maria Romero; Ana Marie Landin; Bonnie B Blomberg
Journal:  Ageing Res Rev       Date:  2010-08-20       Impact factor: 10.895

2.  Quantification of viral proteins of the avian H7 subtype of influenza virus: an isotope dilution mass spectrometry method applicable for producing more rapid vaccines in the case of an influenza pandemic.

Authors:  Wanda I Santana; Tracie L Williams; Emily K Winne; James L Pirkle; John R Barr
Journal:  Anal Chem       Date:  2014-04-11       Impact factor: 6.986

3.  The IgA and subclass IgG responses and protection in mice immunised with influenza antigens administered as ISCOMS, with FCA, ALH or as infectious virus.

Authors:  E T Ben Ahmeida; R Jennings; M Erturk; C W Potter
Journal:  Arch Virol       Date:  1992       Impact factor: 2.574

4.  Morphology and antigenicity studies on reassortant influenza (H3N2) viruses for use in inactivated vaccines.

Authors:  R M Pemberton; R Jennings; T L Smith
Journal:  J Hyg (Lond)       Date:  1985-04

5.  The specificity of the anti-haemagglutinin antibody response induced in man by inactivated influenza vaccines and by natural infection.

Authors:  J S Oxford; G C Schild; C W Potter; R Jennings
Journal:  J Hyg (Lond)       Date:  1979-02

6.  Influenza vaccination in older patients. Immunogenicity, epidemiology and available agents.

Authors:  H Glathe; W Lange
Journal:  Drugs Aging       Date:  1995-05       Impact factor: 3.923

7.  Immunogenicity of influenza and HSV-1 mixed antigen ISCOMs in mice.

Authors:  H O Ghazi; M Erturk; L M Stannard; M Faulkner; C W Potter; R Jennings
Journal:  Arch Virol       Date:  1995       Impact factor: 2.574

8.  Reassortants of influenza B viruses for use in vaccines: an evaluation.

Authors:  A C Goodeve; R Jennings; C W Potter
Journal:  Arch Virol       Date:  1985       Impact factor: 2.574

Review 9.  Challenges of Making Effective Influenza Vaccines.

Authors:  Sigrid Gouma; Elizabeth M Anderson; Scott E Hensley
Journal:  Annu Rev Virol       Date:  2020-05-11       Impact factor: 10.431

10.  Comparative antigenicity and immunogenicity of A/USSR/77 influenza vaccines in normal and primed mice.

Authors:  C McLaren; G E Grubbs; E Staton; W Barthlow; G Quinnan; F A Ennis
Journal:  Infect Immun       Date:  1980-04       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.